TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02620306
Drug: Fimsartan 60mg~120mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict BP control group (SBP \< 130 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level at each visit during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
Study: NCT03005119
Drug: PTL201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two piece acid resistance hard capsule filled with seamless gelatin matrix green beads containing tetrahydrocannabinol (THC) and cannabidiol (CBD). Each capsule contain 5 mg THC and 5 mg CBD
Study: NCT03005119
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo seamless gelatin matrix green beads containing excipients only
Study: NCT03190603
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continue celecoxib 400mg/day for 3months in axial spondyloarthritis patients.
Study: NCT01913314
Drug: [^14C]-LY2835219
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as oral solution
Study: NCT03836222
Drug: PCS499
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR tablet
Study: NCT01400958
Drug: Nuvigil®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nuvigil® 150 mg/day x 42 days THEN, No More Drug
Study: NCT01400958
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo x 42 days; THEN, No More Placebo
Study: NCT00558454
Drug: Iron
Normalized name: Iron
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous succinate mixture
Study: NCT03492866
Drug: Gentamicin Sulfate
Normalized name: Gentamicin Sulfate
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical treatment of 1 side of the scalp twice daily during 6 months
Study: NCT01079949
Drug: r-hLH + r-hFSH
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from stimulation Day 1(S1) at a starting dose of 300-450 International Unit (IU) and then dose adjusted depending on the ovarian response till recombinant human choriogonadotropin (r-hCG) administration day. Recombinant human luteinizing hormone (r-hLH, Luveris®, Lutropin alfa) injection will be administered subcutaneously once daily at a constant dose of 150 IU with flexible start, depending on the follicular growth (when the lead follicle is greater than 14 mm in size), along with r-hFSH treatment as a separate injection till r-hCG administration day.
Study: NCT01079949
Drug: Recombinant Human Choriogonadotropin (r-hCG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The r-hCG will be administered as a single dose of 250-500 microgram (mcg) subcutaneously in the same day after the last dose of the GnRH antagonist.
Study: NCT01204333
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients randomized to standard care will receive (or continue) either intravenous adjusted dose unfractionated heparin (aPTT value kept within 1.5 to 2.5 times the normal value), or any type of body-weight adjusted low molecular weight heparin in therapeutic dose, according to local custom and international guidelines
Study: NCT03102177
Drug: Administration of stable Isotope labeled levothyroxine
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of single dose of stable isotope carbon-13 labeled levothyroxine and measurement of blood levels of stable isotope-labeled levothyroxine
Study: NCT01921946
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00355849
Drug: Human Insulin Inhalation Powder
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient specific dose, inhaled, before meals, 52 weeks
Study: NCT00514202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo
Study: NCT02286557
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00160394
Drug: Duac® Gel / Differin® Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00091936
Drug: Standard TB treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00067470
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00067470
Drug: N-acetylgalactosamine 4-sulfatase
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02120157
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy administration
Study: NCT02195817
Drug: Selincro® 18 mg with continuous psychosocial support: Cohort A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00441103
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered subcutaneously three times a week for 16 weeks.
Study: NCT00873808
Drug: demeclocycline hydrochloride
Normalized name: Demeclocycline Hydrochloride
DrugBank: Demeclocycline (DB00618)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00873808
Drug: ibandronate sodium
Normalized name: Ibandronate Sodium
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00873808
Drug: tetracycline hydrochloride
Normalized name: Tetracycline Hydrochloride
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00873808
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04345406
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: alexoquine
Study: NCT01768468
Drug: JOINS tablet
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet at each time, 3 times a day
Study: NCT00194272
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two dose methotrexate
Study: NCT00016198
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00016198
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00016198
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04621669
Drug: SHR3680
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg
Study: NCT04621669
Drug: Rosuvastatin calcium
Normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg
Study: NCT01848899
Drug: Ioxaglate
Normalized name: ioxaglate
Approvals — FDA: no, EMA: no, PMDA: no
Description: contrast media used during coronary angiography
Study: NCT02449954
Drug: Intravenous ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group III: received IV 30 mg ketorolac tromethamine
Study: NCT00628953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg twice a day
Study: NCT02927873
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses (0.5 mL each for Placebo LD and Placebo HD groups and 0.15 mL each for Placebo MD group) of Placebo administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
Study: NCT02034474
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenously via iv drip over 60 min
Study: NCT03105518
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.5, 1 mcg/kg
Study: NCT03105518
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single + Oxycodone
Study: NCT02387619
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin once daily for 9 days
Study: NCT02387619
Drug: Rosuvastatin and Telmisartan/Amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin and Telmisartan/Amlodipine once daily for 9days
Study: NCT01927419
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching nivolumab
Study: NCT02231294
Drug: Sifrol®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01578057
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.6 g/kg ethanol (women) or 0.7 g/kg ethanol (men) in a total volume of 300 mL as a light cranberry juice cocktail, (consumed within 15 minutes).
Study: NCT00530530
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02947022
Drug: Calcium DTPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: On Day 1, 2.5 mL of Ca-DTPA (1 g/5 mL) will be administered over a period of 1 minute. A solution of normal saline will then be administered at a rate of 300 mL/hr over 30 minutes. Patients will be seated with hands lowered to their sides to allow the chelator to dwell slightly in the soft tissues of the hands and feet. Patients will then be moved to a supine position and the infusion rate increased to 750 mL/hr over the next 60 minutes. At 90 minutes the remaining 2.5 mL of Ca-DTPA will administered IV over a period of 1 minute, and the normal saline will continue for the remaining 9 minutes. The IV line will then be removed. Patients will be instructed to drink plenty of fluids that evening.~The same treatment therapy will consist of 3 time-points, approximately 1 month apart.
Study: NCT02947022
Drug: Zinc DTPA
Normalized name: zinc-DTPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: On Day 2, 2.5 mL of Zn-DTPA (1 g/5 mL) will be administered over a period of 1 minute. A solution of normal saline will then be administered at a rate of 300 mL/hr over 30 minutes. Patients will be seated with hands lowered to their sides to allow the chelator to dwell slightly in the soft tissues of the hands and feet. Patients will then be moved to a supine position and the infusion rate increased to 750 mL/hr over the next 60 minutes. At 90 minutes the remaining 2.5 mL of Zn-DTPA will administered IV over a period of 1 minute, and the normal saline will continue for the remaining 9 minutes. The IV line will then be removed. Patients will be instructed to drink plenty of fluids that evening.~The same treatment therapy will consist of 3 time-points, approximately 1 month apart.
Study: NCT04427917
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo repeated doses
Study: NCT00383721
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo MDI twice a day for 26 weeks
Study: NCT00946569
Drug: JNJ39758979
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive capsule-shaped tablet of JNJ39758979 300mg once daily orally for 12 weeks.
Study: NCT00946569
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo once daily orally for 12 weeks.
Study: NCT03623282
Drug: Synatura® 15 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive Synatura® 15 mL every day three times for 3 months.
Study: NCT00592553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to ataluren will be administered as the schedule specified in the respective arm.
Study: NCT03304470
Drug: ATx201 2% Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anhydrous Cream
Study: NCT03304470
Drug: ATx201 Cream Vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anhydrous Cream
Study: NCT01115738
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose administered once orally
Study: NCT03716518
Drug: Tonifying Spleen and Kidney Sequential Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSKSR will be given to the participants as follows:Liu-jun-an-wei Granule,1 pack each time,twice a day,PO,from 0 to 6th day of chemotherapy and Qi-tu-er-zhi Granule,1 pack each time,twice a day,PO,from 7th to 20th day of chemotherapy.
Study: NCT03716518
Drug: Placebo of 'Tonifying Spleen and Kidney Sequential Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of TCM-TSKSR will be given to the participants as follows:placebo of Liu-jun-an-wei Granule,1 pack each time,twice a day,PO,from 0 to 6th day of chemotherapy and placebo of Qi-tu-er-zhi Granule,1 pack each time,twice a day,from 7th to 20th day of chemotherapy.
Study: NCT04350736
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to be administered by inhalation
Study: NCT05529290
Drug: Dexketoprofen Trometamol + Thiocolchicoside
Normalized name: dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen Trometamol + Thiocolchicoside (25mg + 4mg) is a NSAID. It was given to the patients twice a day.
Study: NCT05529290
Drug: Dexketoprofen Trometamol + Paracetamol
Normalized name: dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen Trometamol + Paracetamol (25mg + 300mg) is a NSAID. It was given to the patients twice a day.
Study: NCT05529290
Drug: Dexketoprofen Trometamol (25mg)
Normalized name: dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen Trometamol (25mg) is a NSAID. It was given to the patients twice a day.
Study: NCT01762306
Drug: Diclofenac Potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02702011
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04325776
Drug: AL2846
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL2846 is a multi-target tyrosine kinase receptor inhibitor with obvious selective to c-met.
Study: NCT04325776
Drug: Zoledronic Acid Injection
Normalized name: zoledronic acid Injection
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid is a bisphosphonate drug that has a strong inhibition of bone resorption and a potential to promote bone formation, and can be used for bone metastasis caused by malignant tumors.
Study: NCT01640990
Drug: GW328267X (total dose of 12mcg)
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mcg/h for 1.5 hours (total dose of 12mcg)
Study: NCT01640990
Drug: GW328267X (total dose of 40mcg)
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mcg/h for 4 hours (total dose of 40 mcg)
Study: NCT01179347
Drug: Placebo Respimat® inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient to receive placebo matching active drug once daily
Study: NCT01985373
Drug: Intravenous immunoglobulin infusion
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood samples are drawn before infusion with Nanogam 50 and Nanogam 100 mg/ml and IgG levels are determined to study PK
Study: NCT00825019
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration in 12h intervals
Study: NCT00852189
Drug: EC0489, Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: PART B: Once PART A MTD is determined, PART B will begin. Dose escalation from a starting dose of 4.2 mg/m2 IV bolus once weekly in a 4-week cycle to the Maximum Tolerated Dose (MTD).
Study: NCT00574119
Drug: spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: spironolactone 50 mg daily for 6 months
Study: NCT03379506
Drug: EBR/GZR FDC Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who are 12 to \<18 years of age will receive oral FDC tablets with EBR 50 mg/GZR 100 mg once daily by mouth.
Study: NCT03379506
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet matched to EBR/GZR FDC tablet.
Study: NCT00020566
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00600028
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 50-100 mg by mouth per day
Study: NCT01925612
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
Study: NCT01925612
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
Study: NCT01969669
Drug: ABT-199
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with ketoconazole
Study: NCT00031499
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single 2 gram oral dose (4 tablets) at Day 1.
Study: NCT00031499
Drug: Benzathine Penicillin
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplied in pre-filled syringes containing 1.2 million units of benzathine penicillin; 2.4 million units administered intramuscularly at Day 1, in one or both buttocks.
Study: NCT00031499
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baseline visit, 28 capsules dispensed, for a dose of 100 mg twice a day (BID).
Study: NCT02831842
Drug: Anti-EGFR-Containing Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.
Study: NCT02831842
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.
Study: NCT01216449
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 250mL of 0.9% sodium chloride solution, infused over 30 minutes
Study: NCT03325556
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, tablets, once daily by mouth
Study: NCT00900445
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT02603354
Drug: peroxide gel tooth bleaching 6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: gel of hygrogen peroxide for teeth bleaching in a low concentration (6%)
Study: NCT01082367
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03934710
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug will be administered in solution form
Study: NCT00348413
Drug: Intravenous Methylprednisolone + Oral Methotrexate vs Intravenous Methylprednisolone + Placebo
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00303758
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00303758
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01662687
Drug: Kytril inj.+Kytril tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days.~Active Comparator arm:~* Kytril inj. 3mg: administered by intravenous infusion at least 5 minutes, just before the first chemotherapy (Day 1).~* Kytril tab. 1mg: administered twice a day by orally at Day 2\~4.
Study: NCT01037452
Drug: Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT01261546
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.~* Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.~* Ranitidine 5 mg/kg IV, q.d. for 2 days.~* Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days.
Study: NCT04184115
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Nasal Gel and placebo patch
Study: NCT02976727
Drug: Placebo cream application
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo cream (indistinguishable from calcipotriol cream by visual and physical appearance and sense of smell) was applied twice for daily on treatment area for 15 consecutive days.
Study: NCT02976727
Drug: MAL application
Normalized name: maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
Study: NCT01037452
Drug: Calcium carbonate/magnesium hydroxide
Normalized name: CALCIUM CARBONATE/MAGNESIUM HYDROXIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT01037452
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT03410927
Drug: TAS0728
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS0728 is an oral HER2 covalent inhibitor investigated in patients with advanced solid tumor harboring HER2 or HER3 abnormalities. It will be administered orally at a starting dose of 50 mg BID each morning and evening and escalated to the DLT. The MTD will be used for the phase 2 arms of the study.
Study: NCT01763463
Drug: New users of ADVAIR DISKUS, ADVAIR HFA (ICS) - containing medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be considered a new user of ICS-containing medications if they had not received a prescription for an ICS-containing medication in the year prior to cohort entry. ICS-containing medications could include ICS and ICS/LABA fixed dose combinations combinations. Patients could not use LABD (long-acting beta-agonists and long-acting antimuscarinics) in the year prior or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.
Study: NCT01763463
Drug: New users of FLOVENT DISKUS, FLVENT HFA (long-acting bronchodilators (LABD))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be considered a new user of LABD medications (long-acting beta-agonists or long-acting antimuscarinics but not both) if they had not received a prescription for an LABD medication in the year prior to cohort entry. Patients could not use ICS-containing medications in the year prior to their new use of LABD or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.